97 related articles for article (PubMed ID: 21382485)
1. Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines.
Park HJ; Qin H; Cha SC; Sharma R; Chung Y; Schluns KS; Neelapu SS; Overwijk WW; Hwu P; Kwak LW
Vaccine; 2011 Apr; 29(18):3476-82. PubMed ID: 21382485
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion.
Marincek BC; Kühnle MC; Srokowski C; Schild H; Hämmerling G; Momburg F
Mol Immunol; 2008 Nov; 46(1):181-91. PubMed ID: 18804283
[TBL] [Abstract][Full Text] [Related]
3. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
4. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
5. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
[TBL] [Abstract][Full Text] [Related]
6. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
9. Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.
Bertholet S; Debrabant A; Afrin F; Caler E; Mendez S; Tabbara KS; Belkaid Y; Sacks DL
Infect Immun; 2005 Oct; 73(10):6620-8. PubMed ID: 16177338
[TBL] [Abstract][Full Text] [Related]
10. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.
Huleatt JW; Jacobs AR; Tang J; Desai P; Kopp EB; Huang Y; Song L; Nakaar V; Powell TJ
Vaccine; 2007 Jan; 25(4):763-75. PubMed ID: 16968658
[TBL] [Abstract][Full Text] [Related]
12. In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine.
Cayeux S; Bukarica B; Buschow C; Charo J; Bunse M; Dörken B; Blankenstein T
Gene Ther; 2007 Oct; 14(20):1481-91. PubMed ID: 17700709
[TBL] [Abstract][Full Text] [Related]
13. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
14. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
15. Vaccine with beta-defensin 2-transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses.
Ma XT; Xu B; An LL; Dong CY; Lin YM; Shi Y; Wu KF
Cancer Res; 2006 Jan; 66(2):1169-76. PubMed ID: 16424055
[TBL] [Abstract][Full Text] [Related]
16. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
Tan XH; Liu C; Wan YH
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
[TBL] [Abstract][Full Text] [Related]
17. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
Gray JC; French RR; James S; Al-Shamkhani A; Johnson PW; Glennie MJ
Eur J Immunol; 2008 Sep; 38(9):2499-511. PubMed ID: 18792403
[TBL] [Abstract][Full Text] [Related]
18. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.
Hamdy S; Molavi O; Ma Z; Haddadi A; Alshamsan A; Gobti Z; Elhasi S; Samuel J; Lavasanifar A
Vaccine; 2008 Sep; 26(39):5046-57. PubMed ID: 18680779
[TBL] [Abstract][Full Text] [Related]
20. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1.
Wang YS; Wang GQ; Wen YJ; Wang L; Chen XC; Chen P; Kan B; Li J; Huang C; Lu Y; Zhou Q; Xu N; Li D; Fan LY; Yi T; Wu HB; Wei YQ
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6779-87. PubMed ID: 18006780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
